DXCM
NASDAQ HealthcareDexCom, Inc. - Common Stock
Medical Devices
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
๐ Market Data
| Price | $61.35 |
|---|---|
| Volume | 10,561,251 |
| Market Cap | 23.67B |
| RSI (14-Day) | 45.0 |
| 200-Day MA | $69.49 |
| 50-Day MA | $65.85 |
| 52-Week High | $89.98 |
| 52-Week Low | $54.11 |
| P/E Ratio | 26.33 |
| Forward P/E | 20.11 |
| Price / Book | 8.01 |
๐ฏ Investment Strategy Scores
DXCM scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Institutional Whale (84/100) โ this strategy Large-cap, institutional-quality stocks.
Lowest fit among scored strategies: ๐ Moon Shot (17/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find DXCM in your text
Paste any article, transcript, or post โ the tool will extract DXCM and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.